Chapter 69: The Idea She Mocked
Celeste's email used the word impossible three times.
Impossible to explain.
Impossible to finance.
Impossible to turn into a platform.
Abandon this direction before you embarrass the company again.
The tribunal read the message into the record without adding tone. The date was two days after Zurich and fourteen months before Celeste claimed the core concept emerged from her leadership.
"I was criticizing the presentation," she said.
"You called the direction impossible," Rhea replied.
"Because Evelyn had not translated it into a viable company program."
"Did you propose the claim relationship as an alternative?"
"I pushed the team to make the work scalable."
"Where is that contribution recorded?"
Celeste returned to the investor slide, the brand presentations, and her broad conversations with staff. Each record came later. None mapped her to the original claim.
Her counsel argued that inventors could doubt an idea before improving it.
The chair agreed.
"Identify the improvement she contributed."
They pointed to no claim element.
The empty claim row remained visible.
She could not fill it.
Sterling requested permission to treat fundraising strategy as the missing improvement. The tribunal refused because no patent claim described an investor narrative or capital structure.
Celeste then said her resistance forced me to refine the idea.
"Challenge can contribute to development," the chair said. "Which mapped concept resulted from your challenge?"
Her counsel pointed to my later work, not a concept she supplied.
I did not need the tribunal to punish her for mocking me. Skepticism was allowed. Scientific work improved because people challenged weak ideas.
What she could not do was turn disbelief into authorship without a record of the contribution that changed her mind.
"Did you answer this email?" the chair asked me.
"Yes."
My reply contained one sentence: I will continue the documented research path and submit the evidence for review.
I had not argued with her market judgment. I kept working.
The next dated record showed a revision responding to an independent technical review, not to Celeste's email. Its witness named the reviewer and described the conceptual change without revealing parameters. Celeste was not listed.
The trust archive showed the next hypothesis version, witness signatures, and claim map progressing from the same direction. Celeste did not appear in those records.
Theo's testimony placed her at later investor visits. Julian's notebook and the Zurich archive placed me explaining the concept before those visits. The author history placed my name first before the incident. Nathan's email showed how it was removed afterward.
No single item decided the hearing.
Together, they formed a sequence Sterling could not reverse by putting three names on a slide.
The tribunal completed every row of the claim map. My records supplied the earliest source for each core element. Celeste's mapped evidence began later and described executive sponsorship, presentation, or opposition rather than conception.
Celeste made one final claim under oath.
"Without my fundraising, her idea would have stayed in a notebook."
"Funding can matter to ownership agreements," the chair said. "It does not make the fundraiser an inventor."
Conrad requested to address the tribunal about the family's contribution. The chair accepted a written ownership statement but refused to merge it into inventorship.
The base patent still belonged to Helena Research Trust. That ownership would not change no matter which sister won scientific credit.
The record closed at the end of the day.
Celeste remained CEO. Nathan remained beside her. Conrad remained chairman. None of them had lost office, and I had gained no company authority.
The tribunal took the claim map, original records, witness limits, and objections under review.
A decision was scheduled for the final week of the third month after the centennial.
Until the written ruling appeared, my public listing remained challenged rather than finally confirmed.